NKE vs PANW: Which Is the Better Buy?

Side-by-side comparison of NIKE, Inc. and Palo Alto Networks, Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
NIKE, Inc. Β· Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction Grade B+
VS
Palo Alto Networks, Inc. Β· Technology
$174.96
+15.2% upside to fair value
Grade B High Quality
QuantHub Verdict
NKE has more upside to fair value (+45.5%). NKE trades at a lower forward P/E (27.9x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric NKE PANW
Current Price $42.62 $174.96
Fair Value Estimate $62.00 $201.61
Upside to Fair Value +45.5% +15.2%
Market Cap $63.0B $119.2B
Forward P/E 27.9x 94.9x
EV / EBITDA 20.7x 52.4x
Price / Sales 1.4x 12.1x
Price / FCF 19.4x 29.3x
Revenue Growth YoY -9.8% +14.9%
Gross Margin 42.7% 73.5%
Operating Margin 8.0% 14.4%
Return on Equity 24.4% 15.5%
Dividend Yield 3.8% 0%
FCF Yield 5.2% 3.41%
Analyst Consensus Buy Strong Buy
Investment Thesis
NKE β€” NIKE, Inc.
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
PANW β€” Palo Alto Networks, Inc.
Palo Alto Networks is a leading cybersecurity company specializing in AI-driven cloud security platforms, subscription services, and hardware products. The company benefits from a durable competitive moat driven by its platform transformation under CEO Nikesh Arora, with over 50% of revenue from high-margin subscription services growing at 25.6% year-over-year in fiscal 2024. Despite a premium va…
Accumulation Zones
Metric NKE PANW
Zone Low $44.00 $151.21
Zone High $50.00 $171.37
In Buy Zone? Yes No
← NKE Research    PANW Research β†’    All Research